HYB_JCV
JC virus infection / Progressive Multifocal Leukoencephalopathy (PML)
Pre-clinicalActive
Key Facts
Indication
JC virus infection / Progressive Multifocal Leukoencephalopathy (PML)
Phase
Pre-clinical
Status
Active
Company
About Hybridize Therapeutics
Hybridize Therapeutics is a private, clinical-stage biotech developing kidney-targeted RNA therapeutics to address a major unmet need in nephrology. Its platform enables the design of chemically modified oligonucleotides with extended half-lives and cell-specific delivery, primarily targeting the proximal tubule epithelial cell (PTEC). The company's lead program, HYB_BKV, is a direct-acting antiviral for BK virus in transplant patients and has been partnered with AiCuris in a deal worth up to €100M, with the program now in Phase 1/2 clinical trials.
View full company profile